AI assistant
DEXCOM INC — Director's Dealing 2021
Mar 11, 2021
30198_dirs_2021-03-10_54fe9709-4872-45ba-b87d-53e3919d1e84.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-03-08
Reporting Person: Blackford Quentin S. (Chief Operating Officer & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-08 | Common Stock | A | 7491 | $0.001 | Acquired | 51674 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021.